GMP Peptides
ZPC has new and comprehensive cGMP standard facilities and professional specialists.
-
Argipressin
QUICK OVERVIEW Product Name: Argipressine CAS No.: 113-79-1 Formular: C46H65N15O12S2 Molar Mass: 1084.23 g/mol Sequence : ［Cys-Tyr-Phe-Gln-Asn-Cys］-Pro-Arg-Gly-NH2 Purity ≥98%; Impurity ≤0.5% ; Storage Temperature 2-8℃; Packing Size 1G/Bottle, 10G/Bottle,50G/Bottle or at customers reqirement. Argpressin is the predominant form of mammalian antidiuretic hormone.
-
Felypressin
Cas No. 56-59-7 Sequence H-Cys-Phe-Phe-Gln-Asn-Cys-Pro-Lys-Gly-NH2 (Disulfide Bridge Cys1-Cys6) Molecular Formula C46H65N13O11S2 Molar Mass 1040.22 g/mol Purity ≥98% Impurity ≤0.5% Storage Temperature 2-8℃ Packing Size 1G/Bottle, 10G/Bottle,50G/Bottle or at customers reqirement. Felypressin can constrict the peripheral blood vessels, increase blood pressure and stop bleeding Application field: Felypressin can constrict the peripheral blood vessels, increase blood pressure and stop bleeding
-
Taspoglutide
CAS: 275371-94-3 Sequence: H2N-His-2-methyl-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-2-methyl-Ala-Arg-CONH2 Molecular Formula: C152H232N40O45 Molar Mass: 3339.74g/mol Purity: ≥98% Synonyms: GLP-1 receptor agonist Fields of Application: Taspoglutide is a pharmaceutical drug, a glucagon-like peptide-1 agonist (GLP-1 agonist), under investigation for treatment of type 2 diabetes being codeveloped by Ipsen and Roche
-
Dalargin
Product Name: Dalargin Cas NO. 81733-79-1 Synonyms: Dalergin; Wound Healing Peptide; Sequence: H-Tyr-D-Ala-Gly-Phe-Leu-Arg-OH Molecular Formula: C35H51N9O8 Formula Weight: 725.83 Purity ≥98%; Impurity ≤0.5% ; Storage Temperature -15℃ Packing Size 1G/Bottle, 10G/Bottle,100G/Bottle or at customers reqirement.
-
Abaloparatide
Full Name：Abaloparatide
CAS No.: 247062-33-5
Sequence: H-Ala-Val-Ser-Glu-His-Gln-Leu-Leu-His-Asp-Lys-Gly-Lys-Ser-Ile-Gln-Asp-Leu-Arg-Arg-Arg-Glu-Leu-Leu-Glu-Lys-Leu-Leu-Aib-Lys-Leu-His-Thr-Ala-NH2
Formular: C174H300N56O49
Molecular Weight: 3960.657 g/mol
Purity：≥98.0%
Impurity ≤0.5% ;
Storage Temperature 2-8℃;
Packing Size 1G/Bottle, 10G/Bottle,50G/Bottle or at customers reqirement.
Abaloparatide, which has less effect on osteoclasts, is an alternative to teriparatide in patients with postmenopausal osteoporosis who are at high risk for fractures or who have failed antiresorptive therapy based on initial clinical studies and economic modeling.Abaloparatide is an analog of PTHrP (parathyroid hormone-related protein). It was approved in April 28, 2017 by the FDA (as Tymlos) for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Abaloparatide is a synthetic peptide that is related to hPTHrP and has demonstrated in preclinical testing the potential to widen the anabolic window for bone therapeutics, stimulating bone formation with a limited effect on bone resorption and mineral mobilization. This could enable improved convenience over currently available anabolic therapies, resulting in greater compliance and, ultimately, greater benefit to patients.
